Rhumbline Advisers Corbus Pharmaceuticals Holdings, Inc. Transaction History

Rhumbline Advisers

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$1.39 - $2.21 $140,242 - $222,975	-100,894 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$1.27 - $3.42 $2,552 - $6,874	-2,010 Reduced 1.95%	100,894 $199,000
Q4 2020 Feb 10, 2021	BUY	$0.94 - $1.89 $13,150 - $26,441	13,990 Added 15.73%	102,904 $129,000
Q3 2020 Nov 12, 2020	SELL	$1.5 - $9.38 $19,425 - $121,471	-12,950 Reduced 12.71%	88,914 $160,000
Q2 2020 Aug 13, 2020	BUY	$4.79 - $8.39 $95,287 - $166,902	19,893 Added 24.27%	101,864 $855,000
Q1 2020 May 06, 2020	BUY	$3.44 - $7.21 $3,852 - $8,075	1,120 Added 1.39%	81,971 $430,000
Q4 2019 Feb 05, 2020	BUY	$4.29 - $5.64 $10,334 - $13,586	2,409 Added 3.07%	80,851 $441,000
Q3 2019 Oct 23, 2019	SELL	$4.87 - $7.08 $1,923 - $2,796	-395 Reduced 0.5%	78,442 $382,000
Q2 2019 Aug 14, 2019	BUY	$6.6 - $7.8 $74,632 - $88,202	11,308 Added 16.75%	78,837 $546,000
Q1 2019 May 01, 2019	BUY	$5.76 - $8.95 $16,358 - $25,417	2,840 Added 4.39%	67,529 $469,000
Q4 2018 Jan 31, 2019	BUY	$5.26 - $7.97 $117,713 - $178,360	22,379 Added 52.89%	64,689 $378,000
Q3 2018 Nov 07, 2018	SELL	$4.65 - $7.95 $14,880 - $25,440	-3,200 Reduced 7.03%	42,310 $319,000
Q2 2018 Aug 06, 2018	BUY	$5.05 - $6.8 $14,695 - $19,788	2,910 Added 6.83%	45,510 $230,000
Q1 2018 May 02, 2018	BUY	$5.6 - $9.25 $31,079 - $51,337	5,550 Added 14.98%	42,600 $260,000
Q4 2017 Feb 09, 2018	SELL	$6.6 - $7.78 $56,727 - $66,869	-8,595 Reduced 18.83%	37,050 $263,000
Q3 2017 Nov 06, 2017	BUY	$5.75 - $7.75 $262,458 - $353,748	45,645	45,645 $326,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $934M
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.